Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001950047-24-000260
Filing Date
2024-01-10
Accepted
2024-01-10 16:13:13
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3329
  Complete submission text file 0001950047-24-000260.txt   5071
Mailing Address C/O MOUNTAIN GROUP CAPITAL, LLC 3835 CLEGHORN AVE., STE. 300 NASHVILLE TN 37203
Business Address C/O MOUNTAIN GROUP CAPITAL, LLC 3835 CLEGHORN AVE., STE. 300 NASHVILLE TN 37203 615-843-9104
MGC VENTURE PARTNERS QP 2018, L.P. (Reporting) CIK: 0001749814 (see all company filings)

EIN.: 831460305 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144

Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Subject) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-41331 | Film No.: 24526731
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)